FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Leap Therapeutics, Inc. Surges After Updated Positive Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab”
Leap Therapeutics, Inc. (NASDAQ: LPTX) surged over 23% in premarket trading after the company presented updated positive data from the first-line cohort of the DisTinGuish study of DKN-01 Plus Tislelizumab.
The study of DKN-01 plus tislelizumab and chemotherapy demonstrated compelling activity, signifying promising results in first line patients with gastric or gastroesophageal junction cancers.
Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap’s most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap has entered into a strategic partnership with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand.
For more information, please visit: Leap Therapeutics, Inc.
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.